Supernus Pharmaceuticals Inc. (SUPN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Supernus Pharmaceuticals Inc. (SUPN) advanced +1.85% to $41.84 as options desks priced 55% call premium vs. 45% put protection around the $41 max-pain magnet. Solid 90% profit margin (-5% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with S
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger.
Moby summary of Supernus Pharmaceuticals, Inc.'s Q3 2026 earnings call
Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will see the combined
Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov.
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Supernus Q3 2026 beats estimates with $226.8M revenue and $0.93 EPS, raises standalone guidance, but upcoming Indivior merger limits stock reaction.
(AP) — Supernus Pharmaceuticals Inc. (SUPN) on Thursday reported profit of $20.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on year to $226.8 million. The company’s full-year revenue guidan
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsJack Khattar - Founder, President, CEO,...
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SUPN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SUPN. Explore sector supply chains on /butterfly.
Why SUPN Stock advanced +1.85% Today — RQD Quant Desk Flash. Solid 90% profit margin (-5% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.